OPKO Health (OPK) News & Sentiment

The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OPKO Health (OPK) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.09 per share a year ago.

MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial.

Evaluate the expected performance of OPKO Health (OPK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.

OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.

We have just released a list of the 11 best NASDAQ penny stocks to invest in at the moment. In this article, we will examine how OPKO Health, Inc. (NASDAQ:OPK) compares to other top NASDAQ penny stocks available for purchase right now. The NASDAQ Stock Market features many of the biggest companies globally.

Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.